Cosentyx

Start

CSU

Ligelizumab

House of Immuno-Dermatology

FA

Auto Injector

CINDU

Remibrutinib

Leaving no stakeholder behind

#1

Smart pack

Flexi Dose

Smart pack

Owning the Urticaria Space with Several Blockbusters

Psoriatic / Rheumatology and Urticaria

2026

2025

2024

2023

2022

2020

2015

CSU

NP

HS

Lichen Plan

IV PsA/AS

JPsA EA

nr-axSpA

Ped Pso

PsO

RCT

AS

CSU

LN

GCA

PsA

PsA

Leading Skin Diseases Management Transformation

Redefining Leadership Through New Indications in Rheumatology

2026

2025

2024

2023

2022

2020

2015

Engagement Partner

APMAATU

Gulf

USD

Million

60

UAE

USD

Million

35

Market Overview

Strategic Focus

Key achievement/ Outcomes

Tactics

Efficacy, access and engagement driven market with full fledge competition

80% for IL17s and IL23s

Reimagining operations Leaving no stakeholder behind

Psoriatic / Rheumatology and Urticaria

Defend Cosentyx as 1st line Bx in PsO

Differentiation in Skin clearance and Complete treatment "WIN IN SKIN"

Empower Patients

Market leader in PSO Since 2017

Enhance customer experience and loyalty

Patient education and activation campaigns to shorten the time for optimal treatment

Through seamless patient access programs

Cosentyx PsO

Revamping support programs

Live Social media educational broadcasts in collaboration with Novartis

Patients

Social Media Campaigns and Targeted Social Media Ads

Patient activation campaigns

Patients

Psoriatic / Rheumatology and Urticaria

Patients

HCS

HCPs

Patients

Leave no stakeholder behind

Pediatric PsO virtual launch

Manchester Virtual PsO Preceptorship

Local Data Generation

My First patient on Cosentyx

Win In Skin campaign

Gulf

USD

Million

25

UAE

USD

Million

13.5

APMAATU

Market Overview

Strategic Focus

Key achievement/ Outcomes

Tactics

Reimagining operations Leaving no stakeholder behind

Enhance customer experience and loyalty

Through seamless patient access programs

Rheum-Derma collaboration

Differentiate to maintain Cosentyx as 1st choice

Differentiation within class Pre-positioning of new entrants

Crowded efficacy and safety driven market, sensitive to patient added-value services

50% for IL17s

Psoriatic / Rheumatology and Urticaria

Market leader in PSA Since 2017

Cosentyx PsA

OCE Cosentyx Rheuma

Cosentyx Connected Care

Patients

Digital Integrated care pathways (DIC PsD)

Revamping support programs

Cosentyx onboarding App

Societies

Smartpack

HCPs

Patients

Patients

PSD clinics

HCS

Psoriatic / Rheumatology and Urticaria

Leave no stakeholder behind

US workshops

Here with you campaign

SPA steering committee

Virtual preceptorship

Commercial standalone

Joint Rheum-Derma P2P meetings

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Psoriatic / Rheumatology and Urticaria

OCE Cosentyx Rheuma

Gulf

USD

Million

15.3

UAE

USD

Million

8.1

Market leader in AS Since 2017 And in AxSPA by end of 2021

APMAATU

Market is driven by patient outcomes

40% for IL17s

Market Overview

Strategic Focus

Reimagining operations Leaving no stakeholder behind

Build and Shape AxSPA Spectrum

Patient activation and Diagnosis acceleration

Drive Cosentyx as 1st choice

Psoriatic/ Rheumatology and Urticaria

Key achievement/ Outcomes

Tactics

AxSPA

Talkback Website

Patients’ meetings

Psoriatic/ Rheumatology and Urticaria

Patients

HCS

HCPs

Patients

Leave no stakeholder behind

Patients’ meetings

Steering committee

Local Data Generation

Cosentyx Academy

Enthesitis summit

IL17 clubhouse

MRI workshops

Social Media

Clarrio

Patient activation

Revamping support programs

MOU-DOH Innovadetect

Societies

UAE

USD

Million

50

Increase in Prescription to change in next 6m

Leading in brand perception and market drivers

Share of voice

Bx naive share

Psoriatic / Rheumatology and Urticaria

Market Share

Gulf

USD

Million

80

Leave no Stakeholder Behind